BIOA
BioAge Labs, Inc.Company Information
- Company Name
- BioAge Labs, Inc.
- CIK
- CIK0001709941
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- BIOA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BIOA
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-10-03
- Last sale
- 2026-06-30
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 398,339
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 37,755,228
- Shares outstanding
- 44,838,893
- Ownership
- 84.20%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- -12.11%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 74 | 242 | 189 | 216 | 220 | 257 | 354 | 334 | ||||||
| Marketable Securities Current | 245 | 141 | 92 | 70 | 77 | 63 | 0 | - | ||||||
| Accounts Receivable Net Current | 1 | 1 | 1 | 1 | 1 | 0 | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 11 | 8 | 5 | 5 | 4 | 4 | 3 | 2 | ||||||
| Assets Current | 330 | 392 | 287 | 291 | 302 | 325 | 357 | 336 | ||||||
| Long Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Marketable Securities | 63 | 2 | 4 | 10 | 16 | 15 | 0 | - | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Assets | 397 | 398 | 295 | 305 | 322 | 344 | 358 | 337 | ||||||
Liabilities Current | ||||||||||||||
| Accounts Payable Current | 6 | 3 | 3 | 5 | 1 | 4 | 2 | 2 | ||||||
| Long Term Debt Current | 0 | 1 | 3 | 4 | 6 | 6 | 6 | 6 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Contract With Customer Liability Current | 4 | 6 | 6 | 8 | 8 | 8 | 8 | - | ||||||
| Liabilities Current | 19 | 16 | 20 | 24 | 23 | 24 | 28 | 19 | ||||||
| Contract With Customer Liability Noncurrent | - | - | 0 | 1 | 2 | 3 | 5 | - | ||||||
| Long Term Debt Noncurrent | - | - | 0 | 0 | 0 | 1 | 3 | 4 | ||||||
| Derivative Liabilities Noncurrent | 1 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 2 | 2 | 3 | 3 | 0 | - | ||||||
| Liabilities | 22 | 19 | 23 | 28 | 27 | 31 | 35 | 24 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | 0 | - | - | - | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Additional Paid In Capital | 757 | 735 | 605 | 585 | 582 | 579 | 576 | 545 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -382 | -356 | -333 | -307 | -287 | -266 | -253 | -232 | ||||||
| Stockholders Equity | 375 | 379 | 272 | 277 | 295 | 313 | 323 | 314 | ||||||
| Liabilities And Stockholders Equity | 397 | 398 | 295 | 305 | 322 | 344 | 358 | 337 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 46 | 44 | 37 | 36 | 36 | 36 | 36 | 34 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | 0 | 0 | ||||||
| Shares Outstanding | 46 | 44 | 37 | 36 | 36 | 36 | 36 | 34 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBioAge Labs, Inc. (BIOA) — SEC Financial Statements & Analysis
BioAge Labs, Inc. (BIOA) is a pharmaceutical preparations company, incorporated in DE. BioAge Labs, Inc. trades on Nasdaq as: BIOA. BioAge Labs, Inc. (BIOA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, BioAge Labs, Inc. carries a market cap of $1.10B, a P/E ratio of -11.63x, a P/B ratio of 2.93x, a P/S ratio of 106.13x, an enterprise value of $1.03B, and an EV/EBITDA multiple of -9.67x. On profitability, it posts an operating margin of -1026.28%, a net margin of -912.25%, a Return on Equity (ROE) of -28.21%, a Return on Assets (ROA) of -26.27%, and a Return on Invested Capital (ROIC) of -55.74%. Per share, it reports EPS of $-2.11, diluted EPS of $-2.11, free cash flow per share of $-1.96, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 168.06% year-over-year, net income growth of -10.55% year-over-year, and EPS growth of -28.48% year-over-year. On the balance sheet, it maintains a current ratio of 17.19x, a quick ratio of 16.62x, working capital of $311.10M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.06, an interest coverage ratio of -378.19x, free cash flow of $-88.09M (TTM), and net debt of $-73.96M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.10B
- P/E TTM
- -11.63x
- EPS TTM
- $-2.11
- P/B TTM
- 2.93x
- ROE TTM
- -28.21%
- ROA TTM
- -26.27%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-88.09M
- Net Revenue TTM Growth 1Y
- 168.06%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BioAge Labs, Inc. in?
BioAge Labs, Inc. (BIOA) operates in the Pharmaceutical Preparations industry.
What exchange does BIOA trade on?
BioAge Labs, Inc. (BIOA) trades on the Nasdaq.
Where is BioAge Labs, Inc. incorporated?
BioAge Labs, Inc. is incorporated in DE.
When was BioAge Labs, Inc. (BIOA)'s most recent SEC filing?
BioAge Labs, Inc. (BIOA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is BIOA's market cap?
BioAge Labs, Inc. (BIOA) has a market capitalization of $1.10B as of 2026-06-30.
What is BIOA's EPS (earnings per share)?
BioAge Labs, Inc. (BIOA)'s trailing twelve month EPS is $-2.11 as of 2026-06-30.
What is BIOA's ROE (return on equity)?
BioAge Labs, Inc. (BIOA)'s trailing twelve month Return on Equity (ROE) is -28.21% as of 2026-06-30.
What is BIOA's ROA (return on assets)?
BioAge Labs, Inc. (BIOA)'s trailing twelve month Return on Assets (ROA) is -26.27% as of 2026-06-30.
What is BIOA's ROIC (return on invested capital)?
BioAge Labs, Inc. (BIOA)'s trailing twelve month Return on Invested Capital (ROIC) is -55.74% as of 2026-06-30.
What is BIOA's EV/EBITDA?
BioAge Labs, Inc. (BIOA)'s trailing twelve month EV/EBITDA is -9.67x as of 2026-06-30.